Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 0.41 |
| ▸ | MERTK | Q12866 | 4/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2074621 | 1.00 | AXL (0.41) | AXLMERTKLRRK2PDCD1CD274 | |
| SCHEMBL987292 | 1.00 | AXL (0.41) | AXLMERTKLRRK2PDCD1CD274 | |
| SCHEMBL985013 | 0.88 | LRRK2 (0.42) | AXLMERTKLRRK2KCNN4 | |
| SCHEMBL985856 | 0.88 | AXL (0.43) | AXLMERTKLRRK2 | |
| SCHEMBL988115 | 0.88 | AXL (0.42) | AXLMERTKLRRK2PDCD1CD274 | |
| SCHEMBL986495 | 0.88 | AXL (0.42) | AXLMERTKLRRK2PDCD1CD274 | |
| SCHEMBL986497 | 0.88 | AXL (0.42) | AXLMERTKLRRK2PDCD1CD274 | |
| SCHEMBL986663 | 0.88 | LRRK2 (0.42) | LRRK2CHEK1ACHEKCNN4 | |
| SCHEMBL985838 | 0.86 | TNIK (0.44) | AXLMERTKLRRK2 | |
| SCHEMBL985532 | 0.84 | KCNN4 (0.37) | LRRK2CHEK1ACHEKCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | claimed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | claimed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | claimed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | claimed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | AXL 503/4885MERTK 30/4885LRRK2 347/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | AXL 503/4885MERTK 30/4885LRRK2 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.